Filing Details

Accession Number:
0001209191-21-048440
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-28 17:00:56
Reporting Period:
2021-07-26
Accepted Time:
2021-07-28 17:00:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1000694 Novavax Inc NVAX Biological Products, (No Disgnostic Substances) (2836) 222816046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610928 Iii A John Herrmann C/O Novavax, Inc.
21 Firstfield Road
Gaithersburg MD 20878
Evp, Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-26 417 $27.60 1,123 No 4 M Direct
Common Stock Acquisiton 2021-07-26 417 $46.00 1,540 No 4 M Direct
Common Stock Acquisiton 2021-07-26 2,062 $5.95 3,602 No 4 M Direct
Common Stock Disposition 2021-07-26 151 $193.09 3,451 No 4 S Direct
Common Stock Disposition 2021-07-26 423 $194.26 3,028 No 4 S Direct
Common Stock Disposition 2021-07-26 263 $195.29 2,765 No 4 S Direct
Common Stock Disposition 2021-07-26 313 $196.12 2,452 No 4 S Direct
Common Stock Disposition 2021-07-26 485 $197.47 1,967 No 4 S Direct
Common Stock Disposition 2021-07-26 317 $198.20 1,650 No 4 S Direct
Common Stock Disposition 2021-07-26 224 $199.47 1,426 No 4 S Direct
Common Stock Disposition 2021-07-26 256 $200.47 1,170 No 4 S Direct
Common Stock Disposition 2021-07-26 209 $201.56 961 No 4 S Direct
Common Stock Disposition 2021-07-26 129 $202.58 832 No 4 S Direct
Common Stock Disposition 2021-07-26 58 $203.45 774 No 4 S Direct
Common Stock Disposition 2021-07-26 68 $204.57 706 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-07-26 417 $0.00 417 $27.60
Common Stock Stock Option (Right to Buy) Disposition 2021-07-26 417 $0.00 417 $46.00
Common Stock Stock Option (Right to Buy) Disposition 2021-07-26 2,062 $0.00 2,062 $5.95
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,095 2027-12-15 No 4 M Direct
7,092 2028-12-13 No 4 M Direct
53,626 2029-09-26 No 4 M Direct
Footnotes
  1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.66 to $193.63, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  3. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.68 to $194.55, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  4. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.755 to $195.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  5. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.80 to $196.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  6. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.80 to $197.79, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  7. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.81 to $198.78, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  8. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.86 to $199.75, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  9. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.89 to $200.88, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  10. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.145 to $202.04, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  11. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.18 to $202.73, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  12. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.37 to $203.86, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  13. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.52 to $204.68, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
  14. Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
  15. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
  16. Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the September 26, 2019 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.